Limitations of the faecal occult blood test in screening for colorectal cancer
- PMID: 10363196
Limitations of the faecal occult blood test in screening for colorectal cancer
Abstract
Background: A screening test should be acceptable, safe, simple, accurate, reliable, effective, and inexpensive. Screening for colorectal cancer with the faecal occult blood test is done to reduce the incidence and mortality from colorectal cancer. How does this test measure up to these requirements?
Methods: The characteristics of faecal occult blood test are described by means of clinical epidemiology, analysing its compliance, sensitivity, specificity, positive predictive value, and its test performance in Bernoulli trials. A decision tree and a Markov model are used to compare the cost-effectiveness of screening strategies involving faecal occult blood test and colonoscopy.
Results: After 5-10 years, patient compliance in a faecal occult blood test screening programme falls below 50%. Over 80% of the patients are likely to leave the programme before its completion. Although the test itself may seem safe and simple, the high rate of false-positive outcomes exposes many subjects to the potential complications of colonoscopy. The high rate of false-negative tests gives patients with colorectal cancer a false sense of security and delays their proper diagnostic work-up. In populations with low prevalence rates of colorectal cancer, faecal occult blood test becomes very inaccurate in diagnosing colorectal cancer, as its positive predictive value falls below 5%. Its long-term test performance is unreliable in that it comes to depend on the frequency, with which the test is repeated. Any negative or positive test result can be achieved by varying the frequency of test repetition. Screening by colonoscopy every five or ten years is more cost-effective than screening by annual faecal occult blood test in preventing the occurrence of colorectal cancer and its associated mortality.
Conclusions: Screening strategies for colorectal cancer involving faecal occult blood test should be abandoned.
Comment in
-
Screening for colorectal neoplasia.Ital J Gastroenterol Hepatol. 1999 Mar;31(2):127-9. Ital J Gastroenterol Hepatol. 1999. PMID: 10363197 No abstract available.
Similar articles
-
Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.Aliment Pharmacol Ther. 2008 Aug 1;28(3):353-63. doi: 10.1111/j.1365-2036.2008.03726.x. Aliment Pharmacol Ther. 2008. PMID: 18638075
-
Fecal occult blood testing: clinical value and limitations.Gastroenterologist. 1998 Mar;6(1):66-78. Gastroenterologist. 1998. PMID: 9531118 Review.
-
Gastric cancer after positive screening faecal occult blood testing and negative assessment.Dig Liver Dis. 2007 Apr;39(4):321-6. doi: 10.1016/j.dld.2006.11.010. Epub 2007 Feb 20. Dig Liver Dis. 2007. PMID: 17314076
-
Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.CMAJ. 1994 Jun 15;150(12):1961-70. CMAJ. 1994. PMID: 7980760 Free PMC article.
-
Screening for colorectal cancer.Tech Coloproctol. 2004 Nov;8 Suppl 1:s10-3. doi: 10.1007/s10151-004-0098-9. Tech Coloproctol. 2004. PMID: 15655587 Review.
Cited by
-
Extracellular Nucleic Acids in the Diagnosis and Progression of Colorectal Cancer.Cancers (Basel). 2022 Jul 29;14(15):3712. doi: 10.3390/cancers14153712. Cancers (Basel). 2022. PMID: 35954375 Free PMC article. Review.
-
Diagnosis of anaemia: old things rearranged.Wien Med Wochenschr. 2012 Nov;162(21-22):478-88. doi: 10.1007/s10354-012-0149-1. Epub 2012 Nov 8. Wien Med Wochenschr. 2012. PMID: 23135251 Review.
-
CorRECTreatment: a web-based decision support tool for rectal cancer treatment that uses the analytic hierarchy process and decision tree.Appl Clin Inform. 2015 Feb 4;6(1):56-74. doi: 10.4338/ACI-2014-10-RA-0087. eCollection 2015. Appl Clin Inform. 2015. PMID: 25848413 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical